rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PYXS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

      Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months Clinical activity consistent across HPV status and prior-treatment subgroups, with a manageable safety profile Results support advancement of MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, planned to initiate in mid-2027 Company to host a live webcast on November 19, 2026, at 7:00 a.m. EST, foll

      5h agoYahoo FinancePYXS
      Pyxis Oncology shareholders approve doubling of authorized common shares
      Nov 13Investing.comPYXS
      Pyxis Oncology at stifel 2026 healthcare conference: micvo nears phase 3
      Nov 10Investing.comPYXSSF
      Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
      Nov 5Yahoo FinancePYXS
      Pyxis Oncology to Participate in Upcoming Investor Conferences
      Oct 28Yahoo FinancePYXS
      Pyxis Oncology to present cancer drug data at Barcelona symposium
      Oct 27Investing.comPYXS
      Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
      Oct 27Yahoo FinancePYXS
      Pyxis: Downgrading To 'Hold' After PYX-106 Dropped And Continued HNSCC Advancement MICVO
      Oct 23Seeking AlphaPYXS
      Pyxis Oncology: Better Runway Is Bullish For MICVO’s Remaining R&D (NASDAQ:PYXS)

      Pyxis Oncology update: The MICVO oncology drug shows promising early data; dosage optimization is ahead. Click for more on PYXS stock.

      Oct 4Seeking AlphaPYXS
      Pyxis Oncology closes $110 million public offering
      Oct 2Investing.comPYXS
      GordonMD global investments acquires Pyxis Oncology common stock By Investing.com
      Oct 2Investing.comPYXS
      Pyxis Oncology Prices Public Offering of Common Stock, Warrants

      Pyxis Oncology (PYXS) has priced a public offering of common stock and warrants for expected gross p

      Sep 30Yahoo FinancePYXS
      Pyxis Oncology prices $110 million public offering
      Sep 30Investing.comPYXS
      Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

      BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of

      Sep 30Yahoo FinancePYXS
      Pyxis Oncology launches public offering of stock and warrants
      Sep 29Investing.comPYXS
      Pyxis Oncology stock falls on public offering announcement
      Sep 29Yahoo FinancePYXS
      Pyxis Oncology Announces Proposed Public Offering

      BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the "Offering") of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stoc

      Sep 29Yahoo FinancePYXS
      Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailPYXS
      Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS)

      Pyxis Oncology receives a "Sell" rating due to high risk, an unproven pipeline, and looming cash constraints. Click here to read more on PYXS.

      Sep 11Seeking AlphaPYXS
      Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

      Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailPYXS
      Pyxis Oncology stock price target raised to $8 by H.C. Wainwright
      Sep 10Investing.comPYXS
      Wells Fargo raises Pyxis Oncology stock price target on MICVO data
      Sep 10Investing.comPYXS
      Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma - Slideshow (NASDAQ:PYXS) 2026-09-10
      Sep 10Seeking AlphaPYXS
      Wedbush raises Pyxis Oncology stock price target on trial data
      Sep 10Investing.comPYXS
      Exclusive BAC Article: Pyxis Oncology; MICVO Monotherapy HNSCC Ph 3 Start Mid-2027, Q4 2026 KEYTRUDA HNSCC Combination Data, And Catalysts (NASDAQ:PYXS)
      Sep 9Seeking AlphaPYXS
      Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
      Sep 9BenzingaPYXS
      Pyxis Oncology shares fall 7% despite updated MICVO trial results

      Pyxis Oncology (NASDAQ:PYXS) shares fell 7% on Tuesday after the biotechnology company released updated Phase 1 data for Micvotabart Pelidotin, or MICVO, in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Among 33 efficacy-evaluable patients receiving MICVO at 5.

      Sep 9Yahoo FinancePYXS
      Pyxis Oncology stock falls 7% despite positive trial data
      Sep 9Investing.comPYXS
      Pyxis Oncology Elevates Thomas Civik to Permanent CEO

      Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailPYXS
      Pyxis Oncology Shares Gain 9.25% After Hours - Pyxis Oncology (NASDAQ:PYXS)
      Sep 9BenzingaPYXS
      Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

      MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups Substantial survival outcomes include median progression-free survival (mPFS) of 6.2 months and 12-month overall survival (OS) probability of 79%, with clinical activity observed across HPV status and prior-treatment subgroups No new safety signals observed; tolerability profile expecte

      Sep 9Yahoo FinancePYXS
      Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating

      Pyxis Oncology (PYXS) has an average rating of buy and mean price target of $7.22, according to anal

      Sep 9Yahoo FinancePYXS
      Pyxis Oncology to present clinical data on cancer therapy
      Sep 8Investing.comPYXS
      Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

      Event to be webcast live on September 9, 2026 at 7:30 a.m. ETBOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) rec

      Sep 8Yahoo FinancePYXS
      Pyxis Oncology names Thomas Civik as permanent CEO and chairman
      Sep 8Investing.comPYXS
      Pyxis Oncology Names Thomas Civik CEO, Board Chairman

      Pyxis Oncology's (PYXS) board appointed Thomas Civik as Chief Executive Officer and Chairman, from S

      Sep 8Yahoo FinancePYXS
      Pyxis Oncology to Participate in Upcoming Investor Conferences

      BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences. Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.2026 Cantor Global Healthcare Conference in New Yor

      Sep 1Yahoo FinancePYXS

      This is the newest page. Registered accounts read further back.